{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"72.7","upperLimit":"131","value":"99.9"},{"groupId":"OG001","lowerLimit":"18.1","upperLimit":"25.9","value":"22.0"},{"groupId":"OG002","lowerLimit":"7.09","upperLimit":"9.71","value":"8.4"},{"groupId":"OG003","lowerLimit":"8.20","upperLimit":"17.3","value":"13.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"}],"units":"Participants"}],"description":"Clearance (CL)","dispersionType":"Full Range","groups":[{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG000","title":"Cohort 1: N-803 - IV 1 ug/kg"},{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG001","title":"Cohort 2: N-803 - IV 3 ug/kg"},{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG002","title":"Cohort 3: N-803 - IV 6 ug/kg"},{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG003","title":"Cohort 4: N-803 - IV 10 ug/kg"}],"paramType":"MEAN","populationDescription":"Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects\n\nCohorts 1-4 - Clearance (CL)","reportingStatus":"POSTED","timeFrame":"PK timepoint up to 72 hours +/- 6 hours","title":"Characterization of the Pharmacokinetic Profile - Clearance (CL)","type":"SECONDARY","unitOfMeasure":"mL/hr/kg"}